The blockade of DAT generates an augmentation of dopamine in the synaptic cleft, improving neurological function disorders involved with emotional approaches, such as learning disabilities, anxiety, anhedonia, and depression [5]. Here, SLC6A3 is linked to depressive symptom measurement.